getimage-48-768x274.png
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
January 25, 2023 08:00 ET | Capricor Therapeutics
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest...
getimage-48-768x274.png
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
January 19, 2023 16:05 ET | Capricor Therapeutics
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023...
getimage-48-768x274.png
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
January 12, 2023 09:26 ET | Capricor Therapeutics
-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
getimage-48-768x274.png
Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 16:01 ET | Capricor Therapeutics
-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Presented Positive One-Year Safety and Efficacy Results From HOPE-2 Open...
getimage-48-768x274.png
Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
November 03, 2022 16:01 ET | Capricor Therapeutics
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
October 06, 2022 09:00 ET | Capricor Therapeutics
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics to Present at Upcoming Investor Conferences
September 07, 2022 08:00 ET | Capricor Therapeutics
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 16:05 ET | Capricor Therapeutics
-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open...
getimage-48-768x274.png
Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
August 03, 2022 08:00 ET | Capricor Therapeutics
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
July 19, 2022 09:15 ET | Capricor Therapeutics
-Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients- -HOPE-3 Builds on Positive Data Results from HOPE-2 Study Recently Published in The...